Methods for identification and modification of lncRNA associated with target genotypes and phenotypes
The application relates to methods for compositions for identifying lncRNA loci associated with target genotypes or phenotypes, including desirable plant genotypes or phenotype. The application also relates to regulatory regions and genes associated with drug resistance, such as resistance to BRAF-inhibitors. Such regulatory regions and genes form the basis for methods for identifying resistance to BRAF-inhibitors, which is useful for improving disease prognosis, treatment, and likely outcomes. The regulatory regions and genes are also suitable targets for therapy in melanoma that is resistant to BRAF-inhibitors.
1. A method of treating melanoma resistant to a BRAF inhibitor, comprising administering to a patient suffering from melanoma resistant to the BRAF inhibitor an effective amount of a BRAF inhibitor and a pharmaceutical composition that inhibits TCONS_00015940 (SEQ ID NO: 170) or a gene regulated by TCONS_00015940 (SEQ ID NO: 170) selected from the group consisting of EQTN, MOB3B, IFNK, and C9orf72, wherein:
TCONS_00015940 (SEQ ID NO: 170) or the gene regulated by TCONS_00015940 (SEQ ID NO: 170) is inhibited by mutating, deleting, or transcriptionally inactivating TCONS_00015940 (SEQ ID NO: 170) or the gene regulated by TCONS_00015940 (SEQ ID NO: 170) by an RNA-guided DNA binding protein, a zinc finger, a zinc finger nuclease (ZFN), a transcription activator-like effector (TALE), a transcription activator-like effector nuclease (TALEN), or a meganuclease;
TCONS_00015940 (SEQ ID NO: 170) or the gene regulated by TCONS_00015940 (SEQ ID NO: 170) is inhibited by downregulating EMICERI or an mRNA transcript of the gene regulated by TCONS_00015940 (SEQ ID NO: 170) with an antisense oligonucleotide (ASO), an interfering RNA, a microRNA, a riboswitch, a ribosome or catalytic RNA, or an RNA-guided RNA binding protein; and/or
the gene regulated by TCONS_00015940 (SEQ ID NO: 170) is inhibited by administration of a small molecule inhibitor against a polypeptide encoded by the gene regulated by TCONS_00015940 (SEQ ID NO: 170) or an antibody that specifically binds the polypeptide encoded by the gene regulated by TCONS_00015940 (SEQ ID NO: 170).
2. The method of claim 1 , wherein the melanoma is selected from the group consisting of nodular melanoma, lentigo maligna, lentigo maligna melanoma, acral lentiginous melanoma, superficial spreading melanoma, mucosal melanoma, polypoid melanoma, desmoplastic melanoma, amelanotic melanoma, and soft-tissue melanoma.
3. The method of claim 1 , wherein the BRAF inhibitor is selected from the group consisting of Vemurafenib, Dabrafenib, Sorafenib, GDC-0879, PLX-4720, and LGX818.
4. The method of claim 1 , wherein the RNA-guided DNA binding protein is a Type-II or Type-V CRISPR-Cas effector.
5. The method of claim 4 , wherein TCONS_00015940 (SEQ ID NO: 170) or the gene regulated by TCONS_00015940 (SEQ ID NO: 170) is inhibited by mutating, deleting, or transcriptionally inactivating TCONS_00015940 (SEQ ID NO: 170) or the gene regulated by TCONS_00015940 (SEQ ID NO: 170) with a non-naturally occurring or engineered composition comprising:
(i) a Type-II or Type-V CRISPR-Cas effector protein or a DNA or mRNA encoding said Type-II or Type-V CRISPR-Cas effector protein, and
(ii) a guide RNA targeting TCONS_00015940 (SEQ ID NO: 170) or the gene regulated by TCONS_00015940 (SEQ ID NO: 170), or a DNA encoding the guide RNA,
wherein the Type-II or Type V CRISPR-Cas effector protein is capable of forming a complex with the guide RNA, and the guide RNA is capable of directing sequence-specific binding of the complex to the target sequence.
6. The method of claim 1 wherein the RNA-guided RNA binding protein is a Type-VI CRISPR-Cas effector.
7. The method of claim 6 , wherein TCONS_00015940 (SEQ ID NO: 170) or the gene regulated by TCONS_00015940 (SEQ ID NO: 170) is inhibited by downregulating EMICERI or an mRNA transcript of the gene regulated by TCONS_00015940 (SEQ ID NO: 170) with a non-naturally occurring or engineered compositions comprising:
(i) a Type-VI CRISPR-Cas effector protein or a DNA or mRNA encoding said Type-VI CRISPR-Cas effector protein, and
(ii) a guide RNA targeting EMICERI or an mRNA transcript of the gene regulated by TCONS_00015940 (SEQ ID NO: 170), or a DNA encoding the guide RNA,
wherein the Type-VI CRISPR-Cas effector protein is capable of forming a complex with the guide RNA, and the guide RNA is capable of directing sequence-specific binding of the complex to the target sequence.
8. The method of claim 5 , wherein the Type-II or Type-V CRISPR-Cas effector protein is not catalytically competent, optionally, the CRISPR-Cas effector is dCas9.
9. The method of claim 5 , wherein the Type-II or Type-V CRISPR-Cas effector protein is catalytically competent, and wherein the non-naturally occurring or engineered composition further comprises an HDR template comprising one or more polyadenylation signal (pAS) sequences.